Biblio

Author [ Keyword(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Abdominal Neoplasms
Holmes WM, Maclellan S, Condon B, Dufès C, Evans TRJ, Uchegbu IF, Schätzlein AG.  2008.  High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil.. Phys Med Biol. 53(2):505-13.
Acrylamides
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R et al..  2009.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.. Int J Oncol. 34(6):1629-36.
Adenocarcinoma
Uchegbu IF, Double JA, Kelland LR, Turton JA, Florence AT.  1996.  The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models.. J Drug Target. 3(5):399-409.
Dufès C, W Keith N, Bilsland A, Proutski I, Uchegbu IF, Schätzlein AG.  2005.  Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.. Cancer Res. 65(18):8079-84.
Adenosine Triphosphatases
Cruz IN, Zhang Y, de la Fuente M, Schätzlein A, Yang M.  2013.  Functional characterization of heat shock protein 90 targeted compounds.. Anal Biochem. 438(2):107-9.
Adhesiveness
Siew A, Le H, Thiovolet M, Gellert P, Schätzlein A, Uchegbu I.  2012.  Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles.. Mol Pharm. 9(1):14-28.
Administration, Buccal
Martin L, Wilson CG, Koosha F, Uchegbu IF.  2003.  Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels.. Eur J Pharm Biopharm. 55(1):35-45.
Administration, Cutaneous
Cevc G, Schätzlein A, Richardsen H.  2002.  Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements.. Biochim Biophys Acta. 1564(1):21-30.
Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G.  1998.  Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin.. Biochim Biophys Acta. 1368(2):201-15.
Administration, Intravenous
Lalatsa A, Schätzlein AG, Garrett NL, Moger J, Briggs M, Godfrey L, Iannitelli A, Freeman J, Uchegbu IF.  2015.  Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration.. J Control Release. 197:87-96.
Administration, Oral
Thompson CJ, Tetley L, Uchegbu IF, Cheng WP.  2009.  The complexation between novel comb shaped amphiphilic polyallylamine and insulin: towards oral insulin delivery.. Int J Pharm. 376(1-2):46-55.
Torrado JJ, Serrano DR, Uchegbu IF.  2013.  The oral delivery of amphotericin B.. Ther Deliv. 4(1):9-12.
Garrett NLaura, Lalatsa A, Uchegbu I, Schätzlein A, Moger J.  2012.  Exploring uptake mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy.. J Biophotonics. 5(5-6):458-68.
Lalatsa A, Lee V, Malkinson JP, Zloh M, Schätzlein AG, Uchegbu IF.  2012.  A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain.. Mol Pharm. 9(6):1665-80.
Cheng WPing, Gray AI, Tetley L, Hang TLe Bich, Schätzlein AG, Uchegbu IF.  2006.  Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds.. Biomacromolecules. 7(5):1509-20.
Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schätzlein AG, Uchegbu IF.  2012.  Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles.. Mol Pharm. 9(6):1764-74.
Adult
Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D et al..  2007.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.. J Clin Oncol. 25(29):4603-9.
Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G.  1998.  Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin.. Biochim Biophys Acta. 1368(2):201-15.
Simpson AB, Calvert PM, Sludden JA, Boddy AV, Griffin MJ, Schatzlein A, Wilson P, Fishwick K, Wheatley A, Ross GA et al..  2002.  Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.. Ann Oncol. 13(3):399-402.
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R et al..  2009.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.. Int J Oncol. 34(6):1629-36.
Aged
Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D et al..  2007.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.. J Clin Oncol. 25(29):4603-9.
Simpson AB, Calvert PM, Sludden JA, Boddy AV, Griffin MJ, Schatzlein A, Wilson P, Fishwick K, Wheatley A, Ross GA et al..  2002.  Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.. Ann Oncol. 13(3):399-402.
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R et al..  2009.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.. Int J Oncol. 34(6):1629-36.
Amino Acid Sequence
Lalatsa A, Schätzlein AG, Uchegbu IF.  2014.  Strategies to deliver peptide drugs to the brain.. Mol Pharm. 11(4):1081-93.
Amino Acids
Brown MD, Schatzlein A, Brownlie A, Jack V, Wang W, Tetley L, Gray AI, Uchegbu IF.  2000.  Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents.. Bioconjug Chem. 11(6):880-91.

Pages